Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy-Reference-Cited by-同舟云学术

Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy

Published:2019-05-15 Issue:7759 Volume:570 Page:112-116
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Di Pilato Mauro,Kim Edward Y.,Cadilha Bruno L.,Prüßmann Jasper N.,Nasrallah Mazen N.,Seruggia Davide,Usmani Shariq M.,Misale Sandra,Zappulli Valentina,Carrizosa Esteban,Mani Vinidhra,Ligorio Matteo,Warner Ross D.,Medoff Benjamin D.,Marangoni Francesco,Villani Alexandra-Chloe,Mempel Thorsten R.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41586-019-1215-2.pdf

Reference44 articles.

1. Savage, P. A., Leventhal, D. S. & Malchow, S. Shaping the repertoire of tumor-infiltrating effector and regulatory T cells. Immunol. Rev. 259, 245–258 (2014).

2. Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480–489 (2011).

3. Spranger, S. et al. Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Transl. Med. 5, 200ra116 (2013).

4. Bauer, C. A. et al. Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction. J. Clin. Invest. 124, 2425–2440 (2014).

5. Meininger, I. & Krappmann, D. Lymphocyte signaling and activation by the CARMA1-BCL10-MALT1 signalosome. Biol. Chem. 397, 1315–1333 (2016).

Cited by 156 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treg Cell Therapeutic Strategies for Breast Cancer: Holistic to Local Aspects;Cells;2024-09-11

2. Infiltrating treg reprogramming in the tumor immune microenvironment and its optimization for immunotherapy;Biomarker Research;2024-09-04

3. Recent developments in immunotherapy for gastrointestinal tract cancers;Journal of Hematology & Oncology;2024-08-09

4. Blood MALT1 serves as a potential biomarker reflecting the response and survival of immune‑checkpoint‑inhibitor therapy in advanced hepatocellular carcinoma;Oncology Letters;2024-08-05

5. Changes in mucosa‑associated lymphoid tissue 1 predicts therapeutic response and survival in patients with advanced melanoma receiving programmed cell death‑1 inhibitor monotherapy;Oncology Letters;2024-07-12